Anzahl der Publikationen: 11
Zeitschriftenartikel
Bruzas, Simona; Gluz, Oleg; Harbeck, Nadia; Schmid, Peter; Cortes, Javier; Blohmer, Jens; Seiberling, Christine; Chiari, Ouafaa; Harrach, Hakima; Ataseven, Beyhan; Shenoy, Satyendra; Dyson, Mark H.; Traut, Eugen; Theuerkauf, Ingo; Gebauer, Daniel; Kuemmel, Sherko und Reinisch, Mattea
(2022):
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response.
In: Npj Breast Cancer, Bd. 8, Nr. 1, 42
Modi, Shanu; Jacot, William; Yamashita, Toshinari; Sohn, Joohyuk; Vidal, Maria; Tokunaga, Eriko; Tsurutani, Junji; Ueno, Naoto T.; Prat, Aleix; Chae, Yee Soo; Lee, Keun Seok; Niikura, Naoki; Park, Yeon Hee; Xu, Binghe; Wang, Xiaojia; Gil-Gil, Miguel; Li, Wei; Pierga, Jean-Yves; Im, Seock-Ah; Moore, Halle C. F.; Rugo, Hope S.; Yerushalmi, Rinat; Zagouri, Flora; Gombos, Andrea; Kim, Sung-Bae; Liu, Qiang; Luo, Ting; Saura, Cristina; Schmid, Peter; Sun, Tao; Gambhire, Dhiraj; Yung, Lotus; Wang, Yibin; Singh, Jasmeet; Vitazka, Patrik; Meinhardt, Gerold; Harbeck, Nadia und Cameron, David A.
(2022):
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
In: New England Journal of Medicine, Bd. 387, Nr. 1: S. 9-20
Hurvitz, Sara A.; Bachelot, Thomas; Bianchini, Giampaolo; Harbeck, Nadia; Loi, Sherene; Park, Yeon Hee; Prat, Aleix; Gilham, Leslie; Boulet, Thomas; Gochitashvili, Nino; Monturus, Estefania; Lambertini, Chiara; Nyawira, Beatrice; Knott, Adam; Restuccia, Eleonora und Schmid, Peter
(2022):
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
In: Future Oncology, Bd. 18, Nr. 32: S. 3563-3572
Winer, Eric P.; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Zhou, Xuan; Karantza, Vassiliki; Mejia, Jaime und Cortes, Javier
(2021):
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
In: Lancet Oncology, Bd. 22, Nr. 4: S. 499-511
Schmid, Peter; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Foukakis, Theodoros; Fasching, Peter A.; Cardoso, Fatima; Untch, Michael; Jia, Liyi; Karantza, Vassiliki; Zhao, Jing; Aktan, Gursel; Dent, Rebecca und O'Shaughnessy, Joyce
(2020):
Pembrolizumab for Early Triple-Negative Breast Cancer.
In: New England Journal of Medicine, Bd. 382, Nr. 9: S. 810-821
Robertson, John F. R.; Evans, Abigail; Henschen, Stephan; Kirwan, Cliona C.; Jahan, Ali; Kenny, Laura M.; Dixon, J. Michael; Schmid, Peter; Kothari, Ashutosh; Mohamed, Omar; Fasching, Peter A.; Cheung, Kwok-Leung; Würstlein, Rachel; Carroll, Danielle; Klinowska, Teresa; Lindemann, Justin P. O.; MacDonald, Alexander; Mather, Richard; Maudsley, Rhiannon; Moschetta, Michele; Nikolaou, Myria; Roudier, Martine P.; Sarvotham, Tinnu; Schiavon, Gaia; Zhou, Diansong; Zhou, Li und Harbeck, Nadia
(2020):
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2(-) Primary Breast Cancer.
In: Clinical Cancer Research, Bd. 26, Nr. 16: S. 4242-4249
Cortes, Javier; Perez-Garcia, Jose Manuel; Llombart-Cussac, Antonio; Curigliano, Giuseppe; El Saghir, Nagi S.; Cardoso, Fatima; Barrios, Carlos H.; Wagle, Shama; Roman, Javier; Harbeck, Nadia; Eniu, Alexandru; Kaufman, Peter A.; Tabernero, Josep; Garcia-Estevez, Laura; Schmid, Peter und Arribas, Joaquin
(2020):
Enhancing global access to cancer medicines.
In: CA : A Cancer Journal for Clinicians, Bd. 70, Nr. 2: S. 105-124
Buchbeitrag
Diese Liste wurde am
Sat Aug 10 19:47:04 2024 CEST
erstellt.